Results 41 to 50 of about 1,663 (174)

Comparison between ziv-aflibercept and ranibizumab for treatment of diabetic macular edema

Journal of the Egyptian Ophthalmological Society
Aim To evaluate safety and efficacy of ziv-aflibercept in comparison to ranibizumab for the treatment of diabetic macular edema (DME). Patients and methods A total of 84 patients (84 eyes) with DME and central macular thickness (CMT) greater than 350 μ ...
Abdalah S. Nasr, Mahmoud A. Ali, Sherif A. Dabbor, Ahmed F. Gabr   +3 more
doaj   +2 more sources

A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer [PDF]

BMC Cancer, 2019
Background Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended phase II dose ...
John H. Strickler, Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S. David Hsu, S. Yousuf Zafar, Michael A. Morse, David Z. Chang, James L. Wells, Kimberly L. Blackwell, P. Kelly Marcom, Christy Arrowood, Emily Bolch, Sherri Haley, Fatima A. Rangwala, Ace J. Hatch, Andrew B. Nixon, Herbert I. Hurwitz   +19 more
doaj   +2 more sources

Ziv-aflibercept: a novel option for the treatment of polypoidal choroidal vasculopathy. [PDF]

BMJ Case Rep, 2015
Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy usually treated using photodynamic therapy (PDT) and antivascular endothelial growth factor agents. However, these cases may sometimes be refractory to both PDT and ranibizumab or bevacizumab, and may have persistent intra-retinal fluid. Recently, studies have reported that aflibercept
Videkar C, Kapoor A, Chhablani J, Narayanan R.   +3 more
europepmc   +6 more sources

Intravitreal Ziv-Aflibercept : Safety Analysis in Eyes Receiving More Than Ten Intravitreal Injections [PDF]

Seminars in Ophthalmology, 2020
Purpose: To report the ocular and systemic adverse events in eyes receiving ≥10 intravitreal ziv-aflibercept (IVZ) injections. Methods: Medical records of patients who received ≥10 IVZ for various chorioretinal conditions with minimum follow up period of
Sumit Randhir Singh, Imoro Zeba Braimah, Jay Chhablani   +2 more
exaly   +3 more sources

FOLFIRI/Ziv-aflibercept Regimen [PDF]

, 2020
National Cancer Institute
openalex   +2 more sources

Ziv-Aflibercept [PDF]

, 2020
National Cancer Institute
openalex   +2 more sources

Safety of 5914 intravitreal ziv-aflibercept injections [PDF]

British Journal of Ophthalmology, 2019
Purpose To analyse the pooled safety data of intravitreal ziv-aflibercept (IVZ) therapy for various retinal conditions. Methods This was a retrospective, observational study which included patients from 14 participating centres who received IVZ.
Andrade, Gabriel Costa, Ashraf, Mohamed, Banker, Alay S., Braimah, Imoro Zeba, Chattannavar, Goura, Chhablani, Jay Kumar, de Oliveira Dias, João Rafael, ElDardeery, Mazen, Farah, Michel Eid, Jabbarpoor Bonyadi, Mohammad Hossein, Maia, André, Mansour, Ahmad Mohammed Farid Mahmoud, Marashi, Ameen, Ramchandani, Suresh J., Ramezani, Alireza Reza, Rodrigues, Eduardo Büchele, Sarvaiya, Chintan, Singh, Sumit Randhir, Soheilian, Masoud, Souka, Ahmed A.R., Stewart, Michael Wesley, Wadhwa, Neeraj   +21 more
core   +3 more sources

Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA [PDF]

Medical Oncology, 2017
Jasmina I Ivanova, Mei Sheng Duh, Francis Vekeman   +2 more
exaly   +2 more sources

Long-term outcome of treat and extend intravitreal ziv-aflibercept therapy [PDF]

British Journal of Ophthalmology, 2019
Aim To assess the 30-month outcome of treat and extend (TAE) intravitreal ziv-aflibercept therapy in eyes with macular diseases. Methods In this prospective study, consecutive subjects received intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections ...
Charbaji, Abdulrazzak, Chhablani, Jay Kumar, Farah, Michel Eid, Mansour, Ahmad Mohammed Farid Mahmoud, Mansour, Hana A.   +4 more
core   +3 more sources

A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G. [PDF]

Target Oncol
Matsumoto T, Yamamoto Y, Kotaka M, Masuishi T, Tsuji Y, Shoji H, Hirata K, Tsuduki T, Makiyama A, Izawa N, Takahashi N, Tsuda M, Yasui H, Ohta T, Kito Y, Otsu S, Hironaka S, Yamazaki K, Boku N, Hyodo I, Yoshimura K, Muro K.   +21 more
europepmc   +3 more sources